Navigation Links
An Oral Disease-Modifying Drug for Relapsing-Remitting Multiple Sclerosis Would Earn High Patient Shares in Both Europe and the United States
Date:2/4/2009

Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral disease-modifying therapy for relapsing-remitting multiple sclerosis would earn a 50 percent patient share in Europe and a 40 percent patient share in the United States, according to surveyed U.S. and European neurologists.

The new report entitled Multiple Sclerosis (Relapsing-Remitting): Emerging Therapies That Offer Improved Convenience Will Not Unseat Current Drugs finds that a therapy's effect on disability is the attribute that most influences surveyed neurologists' prescribing decisions in relapsing-remitting multiple sclerosis. Clinical data and the opinions of interviewed thought leaders indicate that Biogen Idec/Elan's Tysabri has advantages in this attribute over Biogen Idec's Avonex, the market sales leading agent.

Decision Resources' proprietary clinical gold standard in 2008 for relapsing-remitting multiple sclerosis was Tysabri, most notably because of its superior efficacy in the three key aspects of the disease --disability progression, relapses, and lesions -- relative to other agents to treat the disease. Based on its robust efficacy, Tysabri will retain Decision Resources' gold standard status through 2017 for relapsing-remitting multiple sclerosis.

"Although Tysabri is disadvantaged by its rare incidence of life-threatening side effects, we do not expect any therapy in development for relapsing-remitting multiple sclerosis to displace it as the clinical gold standard," said Decision Resources Analyst Bethany Kiernan, Ph.D. "While some therapies in development hold promise, most have efficacy, safety and tolerability, and/or delivery features that surveyed neurologists say are inferior when compared with Tysabri."

About the Report

Multiple Sclerosis (Relapsing-Remitting): Emerging Therapies That Offer Improved Convenience Will Not Unseat Current Drugs is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                           Decision Resources, Inc.
    Christopher Comfort                          Elizabeth Marshall
    781-296-2597                                 781-296-2563
    ccomfort@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Market for Disease-Modifying Osteoarthritis Drugs Will Experience Exponential Growth, Increasing From $477 Million in 2007 to Nearly $3.8 Billion in 2017
2. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
3. New MRI finding sheds light on multiple sclerosis disease progressio
4. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
5. Emory researchers identify signaling protein for multiple myeloma
6. Study suggests brain tumors need treatment with multiple targeted drugs
7. Gene profiling can single out the worst cases of multiple myeloma and guide therapy
8. Cell-surface sugar defects may trigger nerve damage in multiple sclerosis patients
9. Multiple corticosteroid injections in pregnant women may increase cerebral palsy
10. Multiple Sclerosis Patients Find Dietary Treatment More Effective Than Pharmaceutical Regimens
11. IVF technique enables pregnancy without multiple births, Stanford researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... In ... career-focused education and corporate training, and the National Military Family Association, a nonprofit ... Aquino as the second full-tuition scholarship recipient of 2016. , “Being awarded ...
(Date:5/6/2016)... ... May 06, 2016 , ... “ Crossing Over: Affirmations of Faith in ... patients who have allowed those holding vigil to glimpse into the supernatural as their ... to help readers spiritually and practically gain insight into providing care to terminal patients. ...
(Date:5/5/2016)... ... ... While the practice and profession of Aging Life Care is not new, there ... and resources. Aging Life Care plays an important role as these professionals are prepared ... Care is a holistic, client-centered approach to caring for older adults or others facing ...
(Date:5/5/2016)... ... , ... Textile Exchange is excited to announce the release of ... stakeholder review is an important opportunity for interested parties to give input into the ... wool industry., The RWS is intended to be a global benchmark for animal welfare ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to long-term warfarin ... first offering the procedure in April of 2015, Florida Hospital Pepin Heart Institute ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... ZIONA, Israel , May 4, ... TASE: BVXV) announced today that BiondVax,s CEO, Dr. Ron ... conference in New York City . ... at 10:30am at Pioneers 2016, a conference presented by ... York Palace Hotel. The BiondVax presentation that Dr. ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... , May 4, 2016 ... completion of an alternative public offering (APO). This was ... operating company, Valeritas, Inc. and a private placement of ... at $5.00 per share. Under the terms ... 3, 2016, Valeritas Holdings, Inc. will trade on the ...
Breaking Medicine Technology: